Skip to content

US · PRPO · MEDICAL - DIAGNOSTICS & RESEARCH

Precipio, Inc. (PRPO) intrinsic value and stock valuation

$17.35as of 2026-11-21 · Mkt cap 41.88M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Precipio, Inc. DCF and intrinsic value

InvestorsCraft values PRPO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PRPO’s statements →

Precipio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research New Haven, CT 06511 precipiodx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$24.1M+31.6% 5y CAGRd
20112025
Net income
-$-360K
20112025
Free cash flow
$360K
20112025
Total equity
$14.6M+0.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$24.1M$16M$15.2M$9.41M$8.85M
Operating income-$-1.2M-$-4.22M-$-7.62M-$-12.8M-$-9.61M
Net income-$-360K-$-4.29M-$-5.85M-$-12.2M-$-8.55M
EPSd-$-223.6K-$-2.92M-$-4.5M-$-10.7M-$-8.14M
Operating cash flow$690K$440K-$-3.56M-$-7.72M-$-6.58M
Capital expenditure-$-330K-$-220K-$-130K-$-280K-$-680K
Free cash flow$360K$220K-$-3.69M-$-8M-$-7.26M
Total assets$21.3M$17M$18.1M$21.5M$30.4M
Total debt$3.65M$1.25M$1.12M$1.39M$1.43M
Net debt-$-2.39M-$-140K-$-390K-$-2.05M-$-10.24M
Total equity$14.6M$12.1M$14.4M$16.4M$24.6M
Cash and short-term investments$6.04M$1.39M$1.5M$3.44M$11.7M
Income statement
20252024202320222021
Revenue$24.1M$16M$15.2M$9.41M$8.85M
Cost of revenue$13.3M$8.41M$9.18M$6.9M$6.46M
Gross profit$10.7M$7.56M$6.02M$2.51M$2.39M
Research and development expenses$0.00$2.3M$2.7M$2.7M$2.3M
Selling, general and administrative expenses$0.00$11.8M$13.6M$15.3M$12M
Other expenses$11.9M-$-2.3M-$-2.7M-$-2.7M-$-2.3M
Operating expenses$11.9M$11.8M$13.6M$15.3M$12M
Cost and expenses$25.3M$20.2M$22.8M$22.2M$18.5M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$70K$70K$20K$10K$20K
Depreciation and amortization$1.75M$1.51M$1.31M$1.52M$1.44M
Ebitda$1.46M-$-2.7M-$-4.53M-$-10.65M-$-7.05M
Operating income-$-1.2M-$-4.22M-$-7.62M-$-12.8M-$-9.61M
Total other income/expenses, net$840K-$-70K$1.77M$620K$1.1M
Income before tax-$-360K-$-4.29M-$-5.85M-$-12.18M-$-8.52M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-360K-$-4.29M-$-5.85M-$-12.2M-$-8.55M
Weighted average shares outstanding$1.61M$1.47M$1.3M$1.14M$1.05M
Weighted average diluted shares outstanding$1.61M$1.47M$1.3M$1.14M$1.05M
Balance sheet
20252024202320222021
Cash and short-term investments$6.04M$1.39M$1.5M$3.44M$11.7M
Net receivables$1.98M$800K$1.3M$1.04M$700K
Inventory$940K$720K$380K$710K$560K
Total current assets$6.04M$3.45M$3.68M$5.71M$13.5M
Property, plant and equipment, net$4.29M$1.63M$1.52M$1.9M$2.06M
Goodwill and intangible assets$10.9M$11.9M$12.8M$13.8M$14.7M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$15.3M$13.5M$14.4M$15.8M$17M
Total assets$21.3M$17M$18.1M$21.5M$30.4M
Accounts payable$1.13M$620K$620K$2.04M$1.86M
Short-term debt$650K$620K$580K$620K$410K
Deferred revenue$0.00$230K$110K$120K$20K
Total current liabilities$3.75M$4.27M$3.14M$4.36M$4.21M
Long-term debt$3M$630K$530K$780K$1.02M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$3M$630K$530K$780K$1.62M
Capital lease obligations$3.58M$880K$780K$1M$1.24M
Total liabilities$6.76M$4.9M$3.67M$5.14M$5.83M
Common stock$20K$10K$10K$230K$230K
Retained earnings-$-102.8M-$-102.44M-$-98.15M-$-92.3M-$-80.09M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$14.6M$12.1M$14.4M$16.4M$24.6M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$3.65M$1.25M$1.12M$1.39M$1.43M
Net debt-$-2.39M-$-140K-$-390K-$-2.05M-$-10.24M
Cash flow statement
20252024202320222021
Net income-$-360K-$-4.29M-$-5.85M-$-12.18M-$-8.52M
Depreciation and amortization$1.56M$1.51M$1.52M$1.52M$1.44M
Stock-based compensation$1.21M$1.88M$1.74M$3.8M$2.03M
Change in working capital-$-2.17M$1.27M$610K-$-640K-$-400K
Accounts receivable-$-1.36M$440K-$-480K-$-740K$330K
Inventory-$-210K-$-340K$320K-$-140K-$-210K
Accounts payable$510K-$-10K-$-170K$170K$110K
Net cash provided by operating activities$690K$440K-$-3.56M-$-7.72M-$-6.58M
Investments in property, plant and equipment-$-330K-$-220K-$-130K-$-280K-$-680K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-330K-$-220K-$-130K-$-280K-$-680K
Common stock issued$1.38M$80K$2.25M$130K$16.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$900K-$-330K$1.74M-$-230K$16.3M
Net change in cash$1.26M-$-110K-$-1.94M-$-8.22M$9.01M
Cash at end of period$2.65M$1.39M$1.5M$3.44M$11.7M
Operating cash flow$690K$440K-$-3.56M-$-7.72M-$-6.58M
Capital expenditure-$-330K-$-220K-$-130K-$-280K-$-680K
Free cash flow$360K$220K-$-3.69M-$-8M-$-7.26M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Precipio, Inc.

        Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.

        CEO
        Ilan Danieli
        Employees
        61
        Beta
        1.27

        Explore

        Frequently asked questions

        What is the intrinsic value of Precipio, Inc. (PRPO)?

        Precipio, Inc. (PRPO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PRPO undervalued?

        PRPO trades at a price of $17.35 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.